Jim Meyers is a Senior Advisor to and core member of the Health Care practice at the Boston Consulting Group. Over the past five years, Jim has worked directly with 18 of the top-20 pharma companies on a wide variety of healthcare policy and IRA-related projects. Prior to BCG, Jim was one of a small group of executives responsible for building Gilead Sciences from a start-up into one of the most successful biopharmaceutical companies in the world. He served as Gilead’s EVP of Worldwide Commercial Operations and Chief Commercial Officer before retiring in 2018. During his 22-year tenure there, he steered the launch of more than 20 products, including 11 brands with peak annual revenue >$1B, and the two most successful launches in pharmaceutical history as measured by first year revenue, Sovaldi and Harvoni. Jim also serves as the Chairman of the Board of IntegriChain, a Nordic Capital company, and as a Board member for several public and private biotech companies (Arbutus, Cytomx, Sangamo, and Pulmocide). He has a deep understanding of the intersection of public policy, pricing, and access, and the current drug pricing debate in Washington DC.